[New aspects in diagnosis and therapy of placental insufficiency. Placental perfusion measurements; placental perfusion test (PPT) and betamimetic long term treatment (clinical and experimental data (authors transl)].
The rate of utero-placental blood flow depends on functional components (perfusion pressure and flow resistance within the area of the vascular bed of the placenta), as well as on morphological factors (regressive changes in the placenta). Different primary maternal conditions and diseases may lower the rate of placental flow, leading to placental insufficiency; the highest percentage, by far, of placental dysfunction is found in patients suffering from gestosis. Hypocirculation initially present in cases of EPH gestosis and caused by arteriolar spasms triggers off a vicious circle involving placental infarction and severe reduction in the utero-placental perfusion rate. This in turn leads to fetal hypotrophy, a high rate of premature births and perinatal mortality. Verification of HPL, HCG, alpha-Fetoprotein or E3 in maternal serum and amniotic fluid or urine greatly improved the recording of partial placental functions. Along with ultrasonic biometry, cardiotocography and amnioscopy, these hormonal parameters allow only indirect assessment of the placental function. On the other hand, measurements of the utero-placental flow offers a direct approach. In order to evaluate the placental flow measurements it is imperative to obtain a curve indicating the course over the last third of the pregnancy-in addition to establishing a general normal range. In case of placental insufficiency, it is necessary to determine whether this is due to functional disorders alone, or to more extenisve morphological changes. A placental perfusion test (PPT) was developed in order to make this distinction. Beta2-mimetic treatment is indicated if functional factors predominate, whereby it appears essential to obtain the requisite experimental data for precise quantification of beta-mimetic action.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000328:Adult; D000818:Animals; D005260:Female; D006801:Humans; D007204:Indium; D010121:Oxytocin / Q000627:therapeutic use; D010922:Placenta Diseases / Q000175:diagnosis*; D010927:Placental Insufficiency / Q000175:diagnosis* / Q000188:drug therapy; D011225:Pre-Eclampsia / Q000503:physiopathology; D011247:Pregnancy; D011263:Pregnancy Trimester, Third; D011868:Radioisotopes; D012039:Regional Blood Flow / Q000187:drug effects; D012312:Ritodrine / Q000627:therapeutic use; D012643:Selenium; D012756:Sheep; D014168:Transferrin / Q000378:metabolism
D000318:Adrenergic beta-Agonists; D011868:Radioisotopes; D014168:Transferrin; D007204:Indium; D010121:Oxytocin; D012643:Selenium; D012312:Ritodrine
Neue Gesichtspunkte zur Erfassung und Behandlung der Plazentainsuffizienz.